Skip to content
CancerIndex

Publication

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Authors not recorded

Cancer Discov2013PMID 23288408PMC3606893stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
23288408
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
NF1 Mutation2
VemurafenibCutaneous MelanomaALIASPredictiveCSupports Resistance4accepted
EID1470

NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. Knockdown of NF1 led to PLX4720 resistance in-vitro. MEK inhibition with AZD6244 (se… (full text at CIViC)

PMID 23288408 · Whittaker et al., 2013 · Open in CIViC

civic
AZ628 + VTX-11eSubstitutesCutaneous MelanomaALIASPredictiveDSupports Sensitivity Response2accepted
EID1471

NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. BRAF V600E/NF1 mutant cell lines were sensitive to ERK inhibition with VTX-11e, mode… (full text at CIViC)

PMID 23288408 · Whittaker et al., 2013 · Open in CIViC

civic
NF1 R163X1
VemurafenibMelanomaPredictiveCSupports Resistance—submitted
EID4730

In a retrospective study of four relapsed, malignant melanoma patients, NF1 R2450* mutation was associated with acquired resistance to vemurafenib monotherapy in one patient.

PMID 23288408 · Whittaker et al., 2013 · Open in CIViC

civic